Patient recruitment costs continue to increase in clinical trials

According to Earth Times, the patient recruitment step in clinical trials accounts for 23% of the clinical trial time line. They also contribute to the increasing costs of performing clinical trials.

Emerging means for screening potential patients, such as genetic tests, mean that companies must plan for higher lab-testing costs and a lower rate of prospective patient enrollment. And the Canadian Medical Association Journal (CMAJ) in February published an article claiming that drug development costs had increased at a rate 7.4% higher than inflation.

Read the full story here.